Abstract: Lymphoma is a group comprising highly heterogeneous malignancies originating from the lymphatic hematopoietic system and mainly classified into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Lymphoma treatment is mainly systemic, and traditional regimens have reached a bottleneck regarding efficacy and survival of patients with lymphoma. Recently, new drugs and regimens for lymphoma treatment have emerged. Rapid development was observed in immunotherapy, cell therapy, and targeted therapy. With the application of bispecific antibody, antibody-drug conjugate (ADC), and chimeric antigen receptor T-cell (CAR-T), more options were available for patients with lymphoma. The article provides an overview of the recent clinical studies on lymphoma presented at 2022 American Society of Clinical Oncology annual meeting.